These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23845840)

  • 1. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.
    Price JG; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):842-7. PubMed ID: 23845840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
    Lesperance RN; Kjorstadt RJ; Halligan JB; Steele SR
    Am J Surg; 2008 May; 195(5):616-20; discussion 620. PubMed ID: 18374892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
    Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
    Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
    Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
    BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external¬†beam radiation therapy in 2216 patients.
    Tanaka T; Yorozu A; Sutani S; Yagi Y; Nishiyama T; Shiraishi Y; Ohashi T; Hanada T; Saito S; Toya K; Shigematsu N
    Brachytherapy; 2018; 17(5):799-807. PubMed ID: 29936128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel parameter predicting grade 2 rectal bleeding after iodine-125 prostate brachytherapy combined with external beam radiation therapy.
    Shiraishi Y; Hanada T; Ohashi T; Yorozu A; Toya K; Saito S; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):182-7. PubMed ID: 23747214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.
    Kishan AU; Kupelian PA
    Brachytherapy; 2015; 14(2):148-59. PubMed ID: 25516492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
    Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy.
    Mishra MV; Shirazi R; Barrett WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):397-400. PubMed ID: 17956713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management.
    Phan J; Swanson DA; Levy LB; Kudchadker RJ; Bruno TL; Frank SJ
    Cancer; 2009 May; 115(9):1827-39. PubMed ID: 19248043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
    Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal toxicity profile after transperineal interstitial permanent prostate brachytherapy: use of a comprehensive toxicity scoring system and identification of rectal dosimetric toxicity predictors.
    Shah JN; Ennis RD
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):817-24. PubMed ID: 16297567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.